HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS

INTRODUCTION: We have observed that approximately 26% of recurrent gliomas acquire hypermutation following treatment with temozolomide (TMZ). Intriguingly, 91% of these tumors harbor mutations in mismatch repair (MMR) genes. Strategies to target MMR-deficient gliomas thus stand to impact a large num...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Boynton, Adam, Pal, Sangita, Touat, Mehdi, Currimjee, Naomi, Qian, Kenin, Bellamy, Charlotte, Ho, Patricia, Berstler, Jim, Ligon, Keith, Beroukhim, Rameen, Bandopadhayay, Pratiti
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
High Grade Glioma
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715373/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.314
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars